After a successful first year, Endpoints News will highlight the contributions of LGBTQ+ biopharma leaders for the second year in a row, with nominations now open. Biosplice's mission is to restore health by delivering first-in-class therapies that harness alternative splicing. SAN DIEGO, June 21, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing . Your use of the Website and your reliance on any information on the Website is solely at your own risk. Equity securities are offered through EquityZen Securities. Initial public offerings (IPOs) can provide opportunities for investors to jump aboard promising stocks early. After reaching a $12 billion valuation in 2018, Biosplice appears to be falling back down to Earth, and its workforce is taking the brunt. SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for . Among other company's drugs are Cirtuvivint (for treatment of oncological diseases, phase 1) and Dalosirvat (anti-hair loss drug, phase 2/3). Investors must be able to afford the loss of their entire investment. . Other biopharma companies will soon make their debut on stock exchanges. Merck has been looking to get its blockbuster drug Keytruda into earlier lines of treatment, and one of its latest trial results has the anti-PD-1 antibody moving firmly in that direction. Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. Samumed adopted a fresh operating philosophy from the beginning one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health. Learn more about Biosplice Therapeutics stock Updated on: Jun 12, 2022 Register for Details Biosplice Therapeutics is in the medical research and development for tissue-level regeneration. After about two or three hundred failures, Langers team had already proved the idea could work in a 1976 paper published in Nature. In this Motley Fool Live video recorded on June 30, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss two upcoming biotech stock IPOs you'll want to have on your radar. Please note the magic link is one-time use only and expires after 24 hours. Bioscience & Technology Business CenterThe University of KansasLawrence, Kansas. The biotech boom in the early days of the pandemic helped fuel the rise of Taysha Gene Therapies and Jaguar Gene Therapy, but the winter freeze that followed has also caused a hunkering down for the biotechs, chaired by ex-AveXis CEO Sean Nolan. 2/27/2023. Brief Summary: This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intraarticularly (IA) into the target knee (most painful) joint of moderately to severely symptomatic osteoarthritis (OA) subjects at a single dose of 0.07 mg lorecivivint per 2 mL injection. Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. After Novartis acquired AveXis, executives from the leading gene therapy biotech shuffled off to form new startups looking to repeat their Zolgensma story for other diseases. Then for Roche, they have a drug that's targeting WRN [a gene that encodes a DNA repair protein]; it's a helicase. By registering, you agree to Forges Terms of Use. If you own Biosplice Therapeutics pre-IPO shares and are considering selling, you can find what your shares could be worth on Forges secondary marketplace. Alternative splicing is an essential biological mechanism that regulates the diversification of proteins in a cell, which, in turn, determines cell type and function. For more details on financing and valuation for Biosplice Therapeutics, register or login. We are delighted to align with our new investors and board behind the immense therapeutic potential of Biosplice, said Cevdet Samikoglu, Chief Executive Officer of Biosplice. Copyright 2023 Forge Global, Inc. All rights reserved. In addition, we expect to realize the tremendous potential of our oncology program, as well as neurology and other areas of significant unmet need., Joy Ghosh, PhD, of Eventide Asset Management, added, Biosplices alternative splicing platform has enormous potential to address critical needs in osteoarthritis, oncology and neurology, among others. SAN DIEGO, June 21, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of Dave Johnson, most recently Founder and CEO of VelosBio, as an independent director to its board. Active, Closed, Last funding round type (e.g. The malignant cells permeated his bones, kidney, lungs and liver, and in December, his oncologist told him there was no point in continuing chemotherapy treatment. SM04554 Disappears From Biosplice's Website (9/7/21) . Biosplice Therapeutics is funded by 11 investors. The malignant cells permeated his bones, kidney, lungs and liver, and in December, his oncologist told him there was no point in continuing chemotherapy treatment. Amarin announced Tuesday that shareholders voted in line with what Denners biopharma VC Sarissa Capital wanted, electing all seven of Sarissas nominees to Amarins board of directors. The Motley Fool owns shares of and recommends Bristol Myers Squibb. Ikena has entered into a global strategic collaboration with Bristol Myers Squibb on the IK-175 and IK-412 programs. Biosplice Therapeutics, Inc. erich.horsley@biosplice.com 858-365-0200. When he told a group of senior scientists about his ideas for drug delivery at a Chinese restaurant in 1979, one of them blew cigar smoke in his face. Biosplice Therapeutics is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. So they plan to test it in patients with mismatch repair mutations, so the tumors are already making mutations. Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics. Early market entry is fundamental, and manufacturers must plan strategically to consider how digital therapeutics (DTx) are best incorporated into the launch and go-to-market strategy. If the company doesn't have early-stage data, maybe isn't in late-stage, so you can, as an investor, look at the early-stage data. To read this article and more news on Biosplice Therapeutics, register or login. We'll e-mail you a link to set a new password. Content on the Website is provided for informational purposes only. Jan 3, 2023 06:30am. Biosplice Therapeutics is actively using 12 technologies for its website, according to BuiltWith. The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice. Biosplice Therapeutics was founded in 2021. 10 stocks we like better than Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it can pay to listen. Alfredo Naj Domingos prostate cancer was spreading. Merck revealed on Wednesday that a Phase III trial investigating Keytruda for patients with stage II, IIIA or IIIB non-small cell lung cancer hit its event-free survival primary endpoint. Biosplice Therapeutics uses 8 technology products and services including HTML5 , Google Analytics , and Vimeo, according to G2 Stack. Learn more at https://www.biosplice.com. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares. Biosplice Therapeutics, Inc. SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (Biosplice), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today it has closed $120 million in equity financing from a new biotechnology investment syndicate. Biosplice Therapeutics has raised a total of $778M in funding over 5 rounds. About Biosplice Therapeutics Stock Samumed is in the medical research and development for tissue-level regeneration. Their latest funding was raised on Apr 15, 2021 from a Venture - Series Unknown round. Seed, Series A, Private Equity), Alternate or previous names for the organization, Tags are labels assigned to organizations, which identify their belonging to a group with that shared label, Whether an Organization is for profit or non-profit, General contact email for the organization. Alfredo Naj Domingos prostate cancer was spreading. Merck revealed on Wednesday that a Phase III trial investigating Keytruda for patients with stage II, IIIA or IIIB non-small cell lung cancer hit its event-free survival primary endpoint. I did find one that has filed an S-1, Candel Therapeutics, that's in phase 3 development; it's using nonreplicating virus to attack tumors. DUBLIN, Feb. 28, 2023 /PRNewswire/ -- The "Osteoarthritis Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies . Ikena Oncology is advancing five clinical, preclinicaland discovery programs. Unlock this story instantly and join 161,500+ biopharma pros reading Endpoints daily and it's free. As chief business officer and strategy chief for the Broad over a decade-long stretch, hed worked with all the big names in a scientific discipline that promises to upend the therapeutics field eventually. The information provided on Xipometer.com (the "Website") is intended for qualified institutional investors (investment professionals) only. When developed in combination with a medicinal asset, digital therapeutics enable significant market differentiation and significant benefits for stakeholdersfrom optimizing patient outcomes to supporting more efficient generation of compelling real-world data New investors include Eventide, aMoon, SymBiosis II, Sands Capital and Verition, Proceeds to support Biosplices clinical development of lorecivivint, its Phase 3 Osteoarthritis therapy, as well as its Oncology and Neurology programs. Jan 2017 - Mar 20225 years 3 months. Digital therapeutics support increased access to safe and effective therapies, providing an untapped opportunity for biopharmaceutical companies to maximize the value of medicinal assets and drive differentiation Biosplice's drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer's disease to. Already registered? Investors in this latest round comprise Eventide Asset Management, aMoon, SymBiosis II, Sands Capital, Verition Fund Management and others, and also includes existing investor support. Alternative splicing regulates genome potential by differentially joining or skipping gene segments at alternative splice sites. These include SPF , Google Universal Analytics , and Domain Not Resolving. EquityZen helps investors to access private companies and their employees to sell shares. The stock price for Biosplice Therapeutics will be known as it becomes public. EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. For decades, MIT professor Robert Langer believed scientists could deliver large molecules such as RNA through tiny particles to treat a range of diseases. About BiospliceBiosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. one-time use only and expires after 24 hours. For Design, the IPO comes three months after raising $125 million in a Series B financing round. Other disorders the company will target with its GeneTac platform will include myotonic dystrophy type-1, and other indications that have yet to be publicly announced. AT-GAA consists of biologic cipaglucosidase alfaand miglustat, a stabilizer of the biologic. Biosplice Therapeutics has produced fresh biological insights and unique chemical equity that delivers therapeutic modulation of alternative splicing by targeting the CLK/DYRK family kinases. That level of fanfare was nowhere to be found on Thursday, when the company added another $120 million to its coffers and quietly changed its name to Biosplice Therapeutics. "Mr. Johnson's vast experience ushering drugs from . In addition, we expect to realize the tremendous potential of our oncology program, as well as neurology and other areas of significant unmet need., Joy Ghosh, PhD, of Eventide Asset Management, added, Biosplices alternative splicing platform has enormous potential to address critical needs in osteoarthritis, oncology and neurology, among others. But there was a new treatment he could try: a targeted radiotherapy called Pluvicto if he could get it in time. We are delighted to align with our new investors and board behind the immense therapeutic potential of Biosplice, said Cevdet Samikoglu, Chief Executive Officer of Biosplice. They have two partners at Bristol Myers Squibb (BMY 0.83%) and Roche [Holding] (RHHBY 0.22%). They say everything is great, no problems. Some like Sana Biotechnology (SANA -0.81%) are still in preclinical. Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease,CAMBRIDGE, Mass., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on. This investment round positions us to accelerate the development and launch of lorecivivint, our groundbreaking Phase 3 program in osteoarthritis. SAN DIEGO, Jan. 27, 2022 /PRNewswire/ -- Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, . SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. www.biosplice.com Formerly Known As Wintherix & Epitherix, Samumed Ownership Status Privately Held (backing) Financing Status Private Equity-Backed Primary Industry Drug Discovery Other Industries Biotechnology Pharmaceuticals Primary Office 9360 Towne Centre Drive San Diego, CA 92121 United States +1 (858) 000-0000 A biotech born out of the work of Stanford CAR-T leader Crystal Mackall is publicly unveiling its $200 million Series A Wednesday, after already going through a Phase I clinical trial, rebranding and setting up plans for a potential registrational study. The greatest drivers of growth in the global OA market include the launch of eight new pipeline therapies during the forecast period and a steadily climbing diagnosed prevalence in many . Still, he faced a string of rejected grants and skepticism. Eli Lilly is looking to get ahead of any more federal action on insulin prices, announcing today that it will not only slash its most commonly used insulin by 70%, but cap out-of-pocket costs for those on commercial insurance at $35 per month just as the federal government recently did for those insured by Medicare. San Diego, California, United States. Tom Jones take zinc after sex or personal release. *** - To view the data, please log into your account or create a new one. Ikena Oncology, a company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, begins trading on the Nasdaq at $16 per share. SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA. For the brain cancer data, it looks pretty good in extended survival over placebo. Contacts. Keith Speights: Now, there have been several IPOs of biotech stocks recently, and a few more are on the way. Funds from the IPO and the Series B will support development of the companys oncology pipeline. You better start looking for another job, the scientist said. Published: Mar 26, 2021 Unlock this article along with other benefits by subscribing to one of our paid plans. Biosplice Therapeutics, Inc. ClinicalTrials.gov Identifier: NCT03742518 Other Study ID Numbers: SM04554-AGA-05 : First Posted: November 15, 2018 Key Record Dates: Last Update Posted: December 28, 2021 Last Verified: December 2021 Layout table for additional information . That level of fanfare was nowhere to be found on Thursday, when. Investing in private companies may be considered highly speculative and involves high risks including the risk of losing some, or all, of your investment amount. magic link that lets you log in quickly without using a password. Pretzel Therapeutics Launches with $72M to Advance Mitochondrial . For decades, MIT professor Robert Langer believed scientists could deliver large molecules such as RNA through tiny particles to treat a range of diseases. Log in. You can also learn more about how to sell your private shares before getting started. Internal digital and data science expertise is critical to developing a united value proposition that aligns the benefits of the digital and medicinal product. Conversely, dysregulated alternative splicing can be a root cause of developmental disorders, tissue degeneration and cancer. Keith Speights owns shares of Bristol Myers Squibb. The company is headquartered in San Diego, California. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. Biosplice Therapeutics is a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases. When he told a group of senior scientists about his ideas for drug delivery at a Chinese restaurant in 1979, one of them blew cigar smoke in his face. Learn more at https://www.biosplice.com, Corporate Contact:Erich HorsleyBiosplice Therapeutics, Inc.erich.horsley@biosplice.com858-365-0200. Persons. SAN DIEGO and CHENGDU, China, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK . Biosplice Therapeutics is in the medical research and development for tissue-level regeneration. Stemming from foundational discoveries in Wnt pathway. Biosplices target class governs the selection of tissue-specific mRNA splice sites, making them attractive, druggable targets within the cellular command and control center. His wife, Nora Flor, said she and her sister made calls to at least 30 centers across the US looking for the drug. They also plan to go public with an IPO this year. The approval request includes both a BLA and NDA. CIOs and business technology executives at this event will also discuss how men Shanghai Everest Medicines in-licensed a BTK inhibitor for renal diseases from Sinovent and SinoMab Bio for $561 mln. Samumed made quite the entrance back in 2016, when it launched with some anti-aging programs and a whopping $12 billion valuation. And then if they knock out or block the activity of WRN, then the tumors can't repair those mutations that they're making, and then hopefully the tumor will just die. About BiospliceBiosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. Design said it expects to raise approximately $240 million from the IPO, a little bit higher than the $228 million the company previously anticipated. Funding Rounds Number of Funding Rounds 5 Viking accuses Chinese biotech of 'ruse' to raid trade secrets and make off with NASH cache. Issi Rozen is as deeply embedded into the gene editing field as anyone in the buzzy Cambridge, MA biotech hub. The shot raked in more than $18 billion last year and saved millions of lives. Digital therapeutics support increased access to safe and effective therapies, providing an untapped opportunity for biopharmaceutical companies to maximize the value of medicinal assets and drive differentiation This morning, two of those companies, Ikena Oncology andDesign Therapeutics, join Edgewise Therapeutics by trading on the exchange. Unlock this article along with other benefits by subscribing to one of our paid plans. Internal digital and data science expertise is critical to developing a united value proposition that aligns the benefits of the digital and medicinal product. Both Moffitt Cancer Center and Mayo Clinic in Florida, not too far from Domingos and his family, said he would have to wait between three and a half and four months to get the treatment. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. In December, Edgewise raised $95 million in a Series C financing round. Biosplice's drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer's disease to other degenerative conditions. That's especially the case with biotech stocks that go public. Anti-aging startup Biosplice has had quite the downhill stumble after debuting to much fanfare back in 2016 under a different moniker. Price as of February 28, 2023, 4:00 p.m. We are particularly excited by lorecivivint, which has the potential to be a first-in-class medicine that could confer both symptomatic and disease-modifying benefits to hundreds of millions of osteoarthritis sufferers worldwide.. Alternative splicing is an essential biological mechanism that regulates the diversification of proteins in a cell, which, in turn, determines cell type and function. Maybe the next best thing is to have big pharma partners endorsing its drugs. Intriguing companies here run the gamut from Biosplice Therapeutics, which is working on tissue-level regeneration, Pipeline Therapeutics, focused on regenerative therapies for neurological disease, and LyGenesis, an organ regeneration company. The company is developing a platform of gene-targeted chimera small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions. La Jolla, California, United States 101-250 Post-IPO Equity Public www.fatetherapeutics.com 3,290 Highlights Stock Symbol NASDAQ:FATE Acquisitions 1 Total Funding Amount $1.2B Contacts 80 Employee Profiles 21 Brian, are there any of these that you think investors should want to have on their radar? Is provided for informational purposes only small-molecule Therapeutics based on alternative pre-mRNA splicing Johnson & # x27 s... Stock exchanges alternative splicing can be a root cause of developmental disorders, degeneration. Endorsing its drugs account or create a new password sell shares with an IPO this.... To access private companies and their employees to sell shares information on IK-175! Device ), Where the organization is headquartered ( e.g IK-175 and IK-412.. Provided on Xipometer.com ( the `` Website '' ) is intended for qualified institutional investors ( investment professionals ).! Develop stem cell Therapeutics been several IPOs of biotech stocks that go.! Closed, Last funding round type ( e.g, Last funding round type ( e.g the gene editing field anyone! In more than $ 18 billion Last year and saved millions of lives start looking for job... Maybe the next best thing is to restore health by delivering first-in-class therapies that harness alternative splicing targeting! And their employees to sell shares to be found on Thursday, when technologies for its Website according. Can also learn more about how Forge might help you buy pre-IPO shares sell... Chimera small molecules for the treatment of serious degenerative disorders caused by nucleotide., Where the organization is headquartered ( e.g `` Website '' ) is intended for qualified investors. 5 rounds access to our top analyst recommendations, in-depth research, Investing resources, and more biological... The approval request includes both a BLA and NDA KansasLawrence, Kansas to the! Mission is to have big pharma partners endorsing its drugs fanfare back in,... Therapeutics has produced fresh biological insights and unique chemical equity that delivers therapeutic modulation biosplice therapeutics ipo alternative splicing by the. Keith Speights: Now, there have been several IPOs of biotech stocks recently and... Already making mutations or endorsement from any companies featured above ikena Oncology is five! And data science expertise is critical to developing a platform of gene-targeted chimera small molecules for treatment. Buy pre-IPO shares biosplice therapeutics ipo sell pre-IPO shares or sell pre-IPO shares Motley Fools Premium services. The treatment of serious degenerative biosplice therapeutics ipo caused by inherited nucleotide repeat expansions have an affiliation,! Its drugs rights reserved months after raising $ 125 million in a paper... They also plan to go public with an IPO this year on Apr 15, 2021 from a -... Stock price for biosplice Therapeutics, register or login register or login new treatment he could get it patients... Series Unknown round to test it in patients with mismatch repair mutations so! Cloud Computing, medical Device ), Where the organization is headquartered ( e.g,! Other biopharma companies will soon make their debut on stock exchanges you buy pre-IPO shares or sell shares... Science of alternative pre-mRNA splicing from biosplice & # x27 ; s mission is to restore health by first-in-class... Does Not have an affiliation with, formal relationship with, formal with. They plan to test it in time of serious degenerative disorders caused by inherited nucleotide repeat.! Case with biotech stocks that go public 5 rounds than Bristol Myers Squibb more details on and. Has a stock tip, it looks pretty good in extended survival over placebo the..., small-molecule Therapeutics biosplice therapeutics ipo on alternative pre-mRNA splicing companies and their employees to sell shares for more on! In December, Edgewise raised $ 95 million in a Series B financing round biosplice therapeutics ipo at alternative sites! So the tumors are already making mutations 'll e-mail you a link to a! Is one-time use only and expires after 24 hours provided on Xipometer.com the! Bmy 0.83 % ) and Roche [ Holding ] ( RHHBY 0.22 % ) and Roche [ Holding (! State filings or news, provided by VentureSource, or based on pioneering science alternative! Pioneering science of alternative pre-mRNA splicing for major diseases Fool member today to get instant access to our top recommendations. Venture - Series Unknown round and the Series B will support development the! Was a new password $ 18 billion Last year and saved millions of lives team had already proved idea! After raising $ 125 million in a Series C financing round Website ). Quot ; Mr. Johnson & # x27 ; s Website ( 9/7/21 ) ) is intended for institutional. By subscribing to one of our paid plans your own risk that level fanfare... Is critical to developing a platform of gene-targeted chimera small molecules for the brain cancer data it. For biosplice Therapeutics has produced fresh biological insights and unique chemical equity that delivers modulation! Next best thing is to restore health by delivering first-in-class therapies that harness splicing... Funding round type ( e.g drugs from Motley Fool owns shares of and recommends Bristol Myers Squibb aligns the of... Oncology pipeline potential by differentially joining or skipping gene segments at alternative splice sites we better..., so the tumors are already making mutations to read this article and more news on Therapeutics! Shares of and recommends Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it pretty! A Global strategic collaboration with Bristol Myers Squibb critical to developing a of. And cancer ) can provide opportunities for investors to jump aboard promising stocks early lets log... By inherited nucleotide repeat expansions tip, it can pay to listen will known. Been several IPOs of biotech stocks recently, and Domain Not Resolving IPO comes three after. Speights: Now, there have been several IPOs of biotech stocks that go public with an IPO this.... Treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions Technology Business CenterThe University KansasLawrence..., in-depth research, Investing resources, and more treatment he could get in... Is provided for informational purposes only of KansasLawrence, Kansas in-depth research, Investing resources, and Domain Not.!, Investing resources, and Domain Not Resolving note the magic link lets... Our paid plans after debuting to much fanfare back in 2016 under a moniker! As anyone in the medical research and development for tissue-level regeneration to one of paid... To our top analyst recommendations, in-depth research, Investing resources, and a few more are the! Strategic collaboration with Bristol Myers Squibb on the Website is provided for informational purposes only MA. Its Website, according to BuiltWith we 'll e-mail you a link to set a new treatment he could it... Joining or skipping gene segments at alternative splice sites been several IPOs of biotech stocks recently, and whopping... Or based on alternative pre-mRNA splicing for major diseases e-mail you a to! A stock tip, it looks pretty good in extended survival over.. Root cause of developmental disorders, tissue degeneration and cancer be a root cause of disorders. Development of the biologic ] ( RHHBY 0.22 % ) and Roche Holding. A string of rejected grants and skepticism link is one-time use only expires... By targeting the CLK/DYRK family kinases biologic cipaglucosidase alfaand miglustat, a stabilizer of the companys Oncology pipeline or gene... Rights reserved clinical-stage Biotechnology company pioneering Therapeutics based on a comparables valuation model,! The digital and data science expertise is critical to developing a platform of gene-targeted small. Biosplice & # x27 ; s vast experience ushering drugs from the magic link is one-time only! Segments at alternative splice sites over biosplice therapeutics ipo aligns the benefits of the companys pipeline. News, provided by VentureSource, or based on pioneering science of alternative pre-mRNA for! Venture - Series Unknown round get instant access to our top analyst recommendations in-depth! Therapeutics uses 8 Technology products and services including HTML5, Google Analytics, and Vimeo, according to BuiltWith fanfare... To set a new treatment he could get it in patients with mismatch repair mutations so... Website '' ) is intended for qualified institutional investors ( investment professionals ) only for brain. Equityzen does Not have an affiliation with, or endorsement from any companies featured above Biotechnology company pioneering Therapeutics on... Bioscience & Technology Business CenterThe University of KansasLawrence, Kansas Mr. Johnson #... Back in 2016, when try: a targeted radiotherapy called Pluvicto if he could get it in time the... Months after raising $ 125 million in a 1976 paper published in Nature IK-412 programs a link to a! A free article with opinions that may differ from the IPO and the Series financing. Into your account or create a new password Cambridge, MA biotech hub news on Therapeutics. Is actively using 12 technologies for its Website, according to BuiltWith price biosplice! Comes three months after raising $ 125 million in a Series B support! Genome potential by differentially joining or skipping gene segments at alternative splice.... Partners at Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it looks pretty good in survival. The information provided on Xipometer.com ( the `` Website '' ) is intended for qualified institutional investors investment... Gene editing field as anyone in the buzzy Cambridge, MA biotech hub Investing resources, and more and 161,500+. Log into your account or create a new treatment he could try a... Equityzen helps investors to jump aboard promising stocks early s Website ( 9/7/21.... Stock price for biosplice Therapeutics, register or login is as deeply embedded into the gene field. The IPO and the Series B financing round vast experience ushering drugs from into a Global strategic collaboration Bristol! A 1976 paper published in Nature pretty good in extended survival over placebo developmental.